S Yerly

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection
    Jorg Schupbach
    Swiss National Center for Retroviruses, Institute of Medical Virology, University of Zurich, Switzerland
    BMC Infect Dis 12:88. 2012
  2. ncbi Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
    Dimitrios Paraskevis
    Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
    Retrovirology 6:49. 2009
  3. ncbi Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study
    Jan Fehr
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Transl Med 9:14. 2011
  4. ncbi Unusual primary HIV infection with colonic ulcer complicated by hemorrhagic shock: a case report
    Stephane Emonet
    Department of Internal Medicine, University Hospitals Geneva, Rue Gabrielle Perret Gentil 4, Geneva, 1211, Switzerland
    J Med Case Reports 4:279. 2010
  5. ncbi High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease
    Jorg Schupbach
    University of Zurich, Institute of Medical Virology, Swiss National Center for Retroviruses, Zurich, Switzerland
    BMC Infect Dis 11:254. 2011
  6. ncbi Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey
    Sabine Yerly
    Laboratory of Virology, University of Geneva Hospitals, Geneva, Switzerland
    AIDS 21:2223-9. 2007
  7. ncbi Cytomegalovirus quantification in plasma by an automated real-time PCR assay
    Sabine Yerly
    Laboratory of Virology, University of Geneva Hospitals, 24 Rue Micheli du Crest, 1211 Geneva 14, Switzerland
    J Clin Virol 38:298-303. 2007
  8. ncbi [Detection and quantification of nucleic acids in infections diseases: utility and limitations]
    Sabine Yerly
    Laboratoire central de virologie Service des maladies infectieuses Département de médecine interne Hôpitaux universitaires de Genève
    Rev Med Suisse 1:887-90, 893-4. 2005
  9. ncbi [Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)]
    S Yerly
    Laboratoire de Virologie, Hôptal Universitaire de Genève
    Schweiz Med Wochenschr 129:319-22. 1999
  10. ncbi Diagnosing acute HIV infection
    Sabine Yerly
    Laboratory of Virology, Division of Laboratory Medicine, Department of Genetic and Laboratory Medicine, Switzerland
    Expert Rev Anti Infect Ther 10:31-41. 2012

Detail Information

Publications53

  1. ncbi Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection
    Jorg Schupbach
    Swiss National Center for Retroviruses, Institute of Medical Virology, University of Zurich, Switzerland
    BMC Infect Dis 12:88. 2012
    ....
  2. ncbi Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
    Dimitrios Paraskevis
    Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
    Retrovirology 6:49. 2009
    ..However the spatial diffusion of the epidemic from the perspective of the virus has not previously been traced...
  3. ncbi Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study
    Jan Fehr
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Transl Med 9:14. 2011
    ..The aim was to investigate whether the addition of rPRT to genotypic resistance testing (GRT) compared to GRT alone is beneficial for obtaining a virological response in heavily pre-treated HIV-infected patients...
  4. ncbi Unusual primary HIV infection with colonic ulcer complicated by hemorrhagic shock: a case report
    Stephane Emonet
    Department of Internal Medicine, University Hospitals Geneva, Rue Gabrielle Perret Gentil 4, Geneva, 1211, Switzerland
    J Med Case Reports 4:279. 2010
    ..However, although invasion of intestinal lymphoid tissue is a prominent feature of human and simian lentivirus infections, colonic ulceration has not been reported in acute HIV infection...
  5. ncbi High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease
    Jorg Schupbach
    University of Zurich, Institute of Medical Virology, Swiss National Center for Retroviruses, Zurich, Switzerland
    BMC Infect Dis 11:254. 2011
    ..Here, we sought to further investigate the diagnostic specificity of various Inno-Lia algorithms and to identify factors affecting it...
  6. ncbi Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey
    Sabine Yerly
    Laboratory of Virology, University of Geneva Hospitals, Geneva, Switzerland
    AIDS 21:2223-9. 2007
    ..Representative prevalence data of transmitted drug-resistant HIV-1 are essential to establish accurate guidelines addressing resistance testing and first-line treatments...
  7. ncbi Cytomegalovirus quantification in plasma by an automated real-time PCR assay
    Sabine Yerly
    Laboratory of Virology, University of Geneva Hospitals, 24 Rue Micheli du Crest, 1211 Geneva 14, Switzerland
    J Clin Virol 38:298-303. 2007
    ..Sensitive quantitation of cytomegalovirus (CMV) DNA in blood is helpful for the diagnosis of CMV infection or reactivation and the monitoring of transplanted patients...
  8. ncbi [Detection and quantification of nucleic acids in infections diseases: utility and limitations]
    Sabine Yerly
    Laboratoire central de virologie Service des maladies infectieuses Département de médecine interne Hôpitaux universitaires de Genève
    Rev Med Suisse 1:887-90, 893-4. 2005
    ..With the development of antiviral treatments quantitative PCR tests are now essential for the evaluation of treatment efficacy. A discussion with the laboratory is important for the correct interpretation of PCR results...
  9. ncbi [Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)]
    S Yerly
    Laboratoire de Virologie, Hôptal Universitaire de Genève
    Schweiz Med Wochenschr 129:319-22. 1999
    ..The new screening assay was positive before a third-generation anti-HIV screening assay gave positive results in 14/34 patients (41%). Using the DUO assay, the mean reduction of the window period was 4 days...
  10. ncbi Diagnosing acute HIV infection
    Sabine Yerly
    Laboratory of Virology, Division of Laboratory Medicine, Department of Genetic and Laboratory Medicine, Switzerland
    Expert Rev Anti Infect Ther 10:31-41. 2012
    ..We review the clinical presentation of the acute retroviral syndrome, the laboratory markers and their detection methods, and propose an algorithm for the laboratory diagnosis of AHI...
  11. ncbi The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection
    Sabine Yerly
    University of Geneva Medical School, Geneva s University Hospitals, Switzerland
    AIDS 23:1415-23. 2009
    ..To monitor HIV-1 transmitted drug resistance (TDR) in a well defined urban area with large access to antiretroviral therapy and to assess the potential source of infection of newly diagnosed HIV individuals...
  12. ncbi Transforming laboratory test results to improve clinical outcome predictions in HIV patients. Swiss HIV Cohort Study
    T V Perneger
    Institute of Social and Preventive Medicine, University of Geneva Medical School, Switzerland
    J Acquir Immune Defic Syndr Hum Retrovirol 17:442-9. 1998
    ..1 transformation). Natural units of laboratory variables are not optimal for the prediction of clinical events in HIV-infected patients. Which transformation is best depends on the predictor under consideration...
  13. ncbi Acute HIV infection: impact on the spread of HIV and transmission of drug resistance
    S Yerly
    University Hospital of Geneva, 1211 Geneva 14, Switzerland
    AIDS 15:2287-92. 2001
    ....
  14. ncbi Time-dependence of survival predictions based on markers of HIV disease. Swiss HIV Cohort Study
    T V Perneger
    Institute of Social and Preventive Medicine, University of Geneva Medical School, Switzerland
    J Investig Med 48:207-12. 2000
    ..To determine whether the ability of baseline clinical stage, viremia, and CD4 cell counts to predict mortality in HIV-1-infected patients changes with duration of follow-up...
  15. ncbi Nosocomial outbreak of multiple bloodborne viral infections
    S Yerly
    Laboratory of Virology, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    J Infect Dis 184:369-72. 2001
    ..HIV and HCV genotypic analyses identified a HIV monophyletic group, whereas 4 clusters of HCV sequences were identified. To our knowledge, this is the largest documented outbreak of nosocomial HIV transmission...
  16. ncbi Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients
    Bilal Mohty
    University Hospitals of Geneva, Centre for Vaccinology and Neonatal Immunology, Department of Pathology Immunology and Pediatrics, Medical Faculty, Geneva, Switzerland
    Haematologica 96:896-904. 2011
    ..The goal of this study was to assess the efficacy of the AS03-adjuvanted influenza H1N1/A/09 vaccine in allogeneic hematopoietic stem cell transplant recipients...
  17. ncbi Infrequent transmission of HIV-1 drug-resistant variants
    Sabine Yerly
    Laboratory of Virology and AIDS Center, Geneva University Hospital, Geneva, Switzerland
    Antivir Ther 9:375-84. 2004
    ..These data suggest that drug-resistant variants and in particular multidrug-resistant variants have a substantially reduced transmission capacity...
  18. ncbi Clinical relevance of cytomegalovirus viraemia(*,†)
    E Boffi El Amari
    HIV Unit, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    HIV Med 12:394-402. 2011
    ..We investigated the prognostic value of a positive CMV DNA test for the development of CMV end-organ disease, other AIDS-defining events and mortality...
  19. ncbi Zidovudine plus didanosine in primary HIV-1 infection
    L Perrin
    Laboratory of Virology, Geneva University Hospital, Switzerland
    Antivir Ther 2:5-11. 1997
    ..These data suggest a higher efficacy of combined therapy compared with zidovudine monotherapy in PHI patients and indicate that control of viraemia for at least 1 year is achievable in PHI patients...
  20. ncbi High prevalence of non-B HIV-1 subtypes in seamen and their sexual partners in Croatia
    Martha Kathleen Ramirez-Piedad
    Laboratory of Virology, Divisions of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland
    J Med Virol 81:573-7. 2009
    ..Non-B subtypes were found only in individuals with a heterosexual risk, mainly in seamen and their partners...
  21. ncbi Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma
    Florian Bihl
    Department of Gastroenterology and Hepatology, University Hospital Geneva, Geneva, Switzerland
    AIDS 23:1918-22. 2009
    ..These data point toward a potential role of KSHV-specific immunity in the control of AIDS-associated Kaposi's sarcoma...
  22. ncbi Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia
    Tristan Ferry
    Geneva University Hospital, Geneva, Switzerland
    Clin Infect Dis 50:115-8. 2010
    ..Sixteen patients had circulating DNA, with no apparent clinical impact. Erythrovirus-associated anemia is an extremely rare event in HIV-infected patients...
  23. ncbi Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir
    S Yerly
    Laboratory of Virology, University Hospital, Geneva, Switzerland
    Antivir Ther 6:185-9. 2001
    ..In nelfinavir subjects, 30N was the only primary mutation whereas isolated or combined 82A/T and 461/L mutations were detected in indinavir subjects...
  24. ncbi Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy
    L Perrin
    AIDS Centre, Department of Otho Rhino Laryngology, Geneva University Hospital, Switzerland
    J Infect Dis 177:1497-501. 1998
    ..Six subjects had both detectable plasma viremia and evidence of HIV-1 RNA in lymphoid tissue. The results indicate that absence of detectable HIV RNA in lymphoid tissue is associated with viremia levels of HIV-1 RNA <20 copies/mL...
  25. ncbi Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients
    S Yerly
    Central Laboratory of Virology, Geneva University Hospital, Switzerland
    Antivir Ther 1:167-71. 1996
    ..03). These data suggest that there was a better initial CD4 response to didanosine therapy in patients with HIV without the mutation at codon 215, but that this response did not translate into increased survival...
  26. ncbi Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients
    Samir Vora
    Laboratory of Virology, Geneva University Hospital, Switzerland
    AIDS 20:35-40. 2006
    ..CONCLUSIONS: The occurrence of three of the eight mutations in the ATV/RTV genotypic resistance score predicted a clinically identifiable reduced response in patients...
  27. ncbi Travel and the spread of HIV-1 genetic variants
    Luc Perrin
    Laboratory of Virology, Division of Infectious Diseases, University of Geneva, Switzerland
    Lancet Infect Dis 3:22-7. 2003
    ..The spreading of HIV-1 variants has implications for diagnostic, treatment, and vaccine development...
  28. ncbi Drug resistance mutations during structured treatment interruptions
    Sabine Yerly
    Laboratory of Virology, Geneva University Hospital, Switzerland
    Antivir Ther 8:411-5. 2003
    ..55-fold higher in patients with the M184V/I mutation than in patients without detectable mutation (P=0.007). CONCLUSIONS: The M184V/I mutation is frequently selected during repeated treatment interruptions...
  29. ncbi Chronic rhinoviral infection in lung transplant recipients
    Laurent Kaiser
    Central Laboratory of Virology, Division of Infectious Diseases, Department of Internal Medicine, University Hospitals of Geneva, Switzerland
    Am J Respir Crit Care Med 174:1392-9. 2006
    ..Lung transplant recipients are particularly at risk of complications from rhinovirus, the most frequent respiratory virus circulating in the community...
  30. ncbi Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study
    Philippe Brossard
    Department of Gynaecology and Obstetrics, University of Geneva Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
    AIDS 22:2013-7. 2008
    ....
  31. ncbi A prospective trial of structured treatment interruptions in human immunodeficiency virus infection
    Catherine Fagard
    Division of Infectious Diseases, Geneva Unmiversity Hospital, 1211 Geneva 14, Switzerland
    Arch Intern Med 163:1220-6. 2003
    ..Treatment interruptions did not provoke clinical complications, and there was little drug resistance. Comparative trials will have to show what benefit, if any, is associated with intermittent, as opposed to continuous treatment...
  32. ncbi Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study
    Cem Gabay
    University Hospitals of Geneva and University of Geneva, Geneva, Switzerland
    Arthritis Rheum 63:1486-96. 2011
    ..To identify the determinants of antibody responses to adjuvanted split influenza A (H1N1) vaccines in patients with inflammatory rheumatic diseases...
  33. ncbi Increased incidence of sexually transmitted infections in Geneva, Switzerland
    Shahnaz Abraham
    Department of Dermatology and Venereology, University Hospital of Geneva, Geneva, Switzerland
    Dermatology 212:41-6. 2006
    ..CONCLUSION: The situation in Geneva is similar to that observed elsewhere in Western Europe and indicates the need of public health interventions...
  34. ncbi Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact
    Jorge Garbino
    Department of Medicine, Division of Infectious Diseases, Central Laboratory of Virology, University Hospitals of Geneva, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland
    Am J Respir Crit Care Med 170:1197-203. 2004
    ..These viruses were associated with high morbidity, particularly in lung transplant recipients...
  35. ncbi ALK-positive anaplastic large-cell lymphoma: strong T and B anti-tumour responses may cause hypocellular aspects of lymph nodes mimicking inflammatory lesions
    B Borisch
    Department of Pathology, University Hospital of Geneva, Geneva, Switzerland
    Eur J Haematol 71:243-9. 2003
    ..Hypocellular and oedematous lymph nodes occurring in a child with evocative symptoms should be tested for the presence of ALK...
  36. ncbi A patient with HIV-1 superinfection
    Stephanie Jost
    Division of Infectious Diseases, University of Geneva, Geneva
    N Engl J Med 347:731-6. 2002
  37. ncbi A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
    Milos Opravil
    Division of Infectious Diseases, University Hospital, CH 8091 Zurich, Switzerland
    J Infect Dis 185:1251-60. 2002
    ....
  38. ncbi HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:451-5. 2008
    ..We studied gp41 mutations associated with failing enfuvirtide salvage therapy...
  39. ncbi Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Clin Infect Dis 46:1299-309. 2008
    ..We aimed to identify predictors for the emergence of K65R, using clinical data and genotypic resistance tests from the Swiss HIV Cohort Study...
  40. ncbi Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
    Annemarie M J Wensing
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, The Netherlands
    J Infect Dis 192:958-66. 2005
    ..These data argue for testing all drug-naive patients and are of relevance when guidelines for management of postexposure prophylaxis and first-line therapy are updated...
  41. ncbi HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 40:250-6. 2005
    ..Persisting p24 despite successful HAART may reflect virus replication in reservoirs not represented by plasma viral load and has implications for the concept of therapeutic vaccination...
  42. ncbi HIV-1 co/super-infection in intravenous drug users
    Sabine Yerly
    AIDS 18:1413-21. 2004
    ..In chronically infected IVDUs super-infection may be transient and may occur in patients controlling efficiently HIV infection by the initial strain...
  43. ncbi The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
    David A van de Vijver
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, G04-614, 3584 CX Utrecht, The Netherlands
    J Acquir Immune Defic Syndr 41:352-60. 2006
    ..Because of differences in minor protease substitutions, protease inhibitor resistance could be enhanced in particular subtypes once the relevant major substitutions are selected...
  44. ncbi Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study
    Dominique Costagliola
    INSERM, Unité Mixte de Recherche UMR S 720, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Acquir Immune Defic Syndr 46:12-8. 2007
    ..Surveillance of HIV-1 drug resistance in antiretroviral-treated patients is important from the public health perspective of the spread of resistance and to evaluate the proportion of patients for whom new drugs are needed...
  45. ncbi Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistr 100, CH 8091 Zurich, Switzerland
    Arch Intern Med 167:1782-90. 2007
    ..Differences between these regimen types in the extent of the emergence of drug resistance on virological failure and the implications for further treatment options have rarely been assessed...
  46. ncbi Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation
    Jorg Schupbach
    University of Zurich, Swiss National Center for Retroviruses, Zurich, Switzerland
    PLoS Med 4:e343. 2007
    ..We have investigated whether this "recency" information can also be gained from an HIV confirmatory assay...
  47. ncbi Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
    Marcel Wolbers
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    AIDS 21:2201-7. 2007
    ....
  48. ncbi Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions
    Sabine Yerly
    AIDS 18:1951-3. 2004
    ....
  49. ncbi CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    Lancet 368:459-65. 2006
    ..Treatment-related adverse events were more frequent with continuous treatment, but low CD4 counts and minor manifestations of HIV infection were more frequent with scheduled treatment interruption...
  50. ncbi The trap: professional exposure to human immunodeficiency virus antibody negative blood with high viral load
    Stefano Giulieri
    Service of Infectious Diseases, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    Arch Intern Med 167:2524-6. 2007
  51. ncbi Amplicon sequencing and improved detection of human rhinovirus in respiratory samples
    Christelle Deffernez
    Central Laboratory of Virology, Division of Infectious Diseases, Department of Internal Medicine, University Hospitals of Geneva, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland
    J Clin Microbiol 42:3212-8. 2004
    ..By sequencing the 5' noncoding regions of rhinoviruses recovered from clinical specimens, we designed probes that could specifically detect rhinovirus...